Tuesday, September 9, 2008

Gryphon Investors Invests in CROs

PharmaTimes reports Gryphon Investors has announced an agreement with two US suppliers of clinical services to pharmaceutical and biotechnology industries.

Gryphon has invested funds in Synteract, which is a CRO with expertise in oncology and central nervous system drugs, and Vince Associates, which is a leading provider of services that specialize in sleep disorders research. Nick Orum, head of Gryphon’s Business Services Group mentions that the agreement has been a “year-long effort … to become an active participant in the dynamic, growing field of outsourced drug development services”.

No comments:

Post a Comment